title: A 475 years-old founder effect involving IL12RB1: a highly prevalent mutation conferring Mendelian Susceptibility to Mycobacterial Diseases in European descendants.
abstract: Mutations in IFNGR1, IFNGR2, IL12RB1, IL12B, STAT1 and NEMO result in a common clinical phenotype known as Mendelian Susceptibility to Mycobacterial Diseases (MSMD). Interleukin-12 receptor beta1 (IL-12Rbeta1) deficiency is the most common genetic etiology for MSMD. Known mutations affecting IL12RB1 are recessively inherited and are associated with null response to both IL-12 and IL-23. Mutation IL12RB1 1623_1624delinsTT was originally described in 5 families from European origin (2 from Germany; 1 from Cyprus, France and Belgium). Interestingly, this same mutation was found in an unexpectedly high prevalence among IL-12Rbeta1 deficient patients in Argentina: 5-out-of-6 individuals born to unrelated families carried this particular change. To determine whether mutation 1623_1624delinsTT represents a DNA mutational hotspot or a founder effect, 34 polymorphic markers internal or proximal to IL12RB1 were studied in the Argentinean and the Belgian patients. A common haplotype spanning 1.45-3.51Mb was shared by all chromosomes carrying mutation 1623_1624delinsTT, and was not detected on 100 control chromosomes. Applying a modified likelihood-based method the age of the most recent common ancestor carrying mutation 1623_1624delinsTT was estimated in 475 years (95% CI, 175-1275), which is the time when the Spaniards initiated the colonization of the Americas. Mutation 1623_1624delinsTT represents the first founder effect described on IL-12Rbeta1, the most frequently affected gene in MSMD, and affecting patients with European ancestors. The reason(s) behind the persistency of this mutation across multiple generations, its relative high prevalence, and any potential selective advantage are yet to be established.
authors.affiliation: Hospital Nacional de Pediatría JP Garrahan, Buenos Aires, Argentina.
authors.forename: J
authors.initials: J
authors.lastname: Yancoski
authors.forename: C
authors.initials: C
authors.lastname: Rocco
authors.forename: A
authors.initials: A
authors.lastname: Bernasconi
authors.forename: M
authors.initials: M
authors.lastname: Oleastro
authors.forename: L
authors.initials: L
authors.lastname: Bezrodnik
authors.forename: C
authors.initials: C
authors.lastname: Vrátnica
authors.forename: F
authors.initials: F
authors.lastname: Haerynck
authors.forename: S D
authors.initials: SD
authors.lastname: Rosenzweig
mesh_terms: D000818:Animals; D001118:Argentina; D001500:BCG Vaccine / Q000008:administration & dosage / Q000009:adverse effects; D018703:Founder Effect; D020022:Genetic Predisposition to Disease; D006801:Humans; D015810:Linkage Disequilibrium; D008957:Models, Genetic; D009154:Mutation; D009164:Mycobacterium Infections / Q000235:genetics*; D009163:Mycobacterium bovis / Q000302:isolation & purification; D053707:Receptors, Interleukin-12 / Q000235:genetics*; D044465:White People / Q000235:genetics
chemical_list: D001500:BCG Vaccine; C508438:IL12RB1 protein, human; D053707:Receptors, Interleukin-12